$CASC Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Cascadian Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Cascadian Therapeutics, Inc.. Get notifications about new insider transactions in Cascadian Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Sep 20 2017 | CASC | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Option Exercise | A | 0.00 | 15,500 | 0 | 15,500 | |
Sep 20 2017 | CASC | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Option Exercise | A | 3.99 | 60,000 | 239,400 | 60,000 | |
Aug 14 2017 | CASC | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Buy | P | 3.74 | 5,500 | 20,543 | 49,716 | 44.2 K to 49.7 K (+12.44 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Option Exercise | M | 0.00 | 9,058 | 0 | 0 | |
Jun 27 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Payment of Exercise | F | 3.78 | 2,265 | 8,562 | 19,225 | 21.5 K to 19.2 K (-10.54 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Buy | M | 0.00 | 9,058 | 0 | 21,490 | 12.4 K to 21.5 K (+72.86 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | LOVE TED W | Director | Option Exercise | M | 0.00 | 9,058 | 0 | 0 | |
Jun 27 2017 | CASC | Cascadian Therapeu ... | LOVE TED W | Director | Payment of Exercise | F | 3.78 | 2,265 | 8,562 | 35,613 | 37.9 K to 35.6 K (-5.98 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | LOVE TED W | Director | Buy | M | 0.00 | 9,058 | 0 | 37,878 | 28.8 K to 37.9 K (+31.43 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | James Steven P | Director | Option Exercise | M | 0.00 | 9,058 | 0 | 0 | |
Jun 27 2017 | CASC | Cascadian Therapeu ... | James Steven P | Director | Payment of Exercise | F | 3.78 | 2,265 | 8,562 | 11,896 | 14.2 K to 11.9 K (-15.99 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | James Steven P | Director | Buy | M | 0.00 | 9,058 | 0 | 14,161 | 5.1 K to 14.2 K (+177.50 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | HENNEY CHRISTOPHER S | Director | Option Exercise | M | 0.00 | 9,058 | 0 | 0 | |
Jun 27 2017 | CASC | Cascadian Therapeu ... | HENNEY CHRISTOPHER S | Director | Payment of Exercise | F | 3.78 | 2,265 | 8,562 | 58,404 | 60.7 K to 58.4 K (-3.73 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | HENNEY CHRISTOPHER S | Director | Buy | M | 0.00 | 9,058 | 0 | 60,669 | 51.6 K to 60.7 K (+17.55 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | Fyfe Gwen A. | Director | Option Exercise | M | 0.00 | 9,058 | 0 | 0 | |
Jun 27 2017 | CASC | Cascadian Therapeu ... | Fyfe Gwen A. | Director | Payment of Exercise | F | 3.78 | 2,265 | 8,562 | 10,125 | 12.4 K to 10.1 K (-18.28 %) |
Jun 27 2017 | CASC | Cascadian Therapeu ... | Fyfe Gwen A. | Director | Buy | M | 0.00 | 9,058 | 0 | 12,390 | 3.3 K to 12.4 K (+271.85 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Option Exercise | M | 0.00 | 2,148 | 0 | 0 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 0.00 | 13,927 | 0 | 13,927 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Payment of Exercise | F | 3.34 | 537 | 1,794 | 12,432 | 13 K to 12.4 K (-4.14 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Buy | M | 0.00 | 2,148 | 0 | 12,969 | 10.8 K to 13 K (+19.85 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | LOVE TED W | Director | Option Exercise | M | 0.00 | 2,148 | 0 | 0 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | LOVE TED W | Director | Option Exercise | A | 0.00 | 13,927 | 0 | 13,927 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | LOVE TED W | Director | Payment of Exercise | F | 3.34 | 537 | 1,794 | 28,820 | 29.4 K to 28.8 K (-1.83 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | LOVE TED W | Director | Buy | M | 0.00 | 2,148 | 0 | 29,357 | 27.2 K to 29.4 K (+7.89 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | James Steven P | Director | Option Exercise | M | 0.00 | 2,148 | 0 | 0 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | James Steven P | Director | Option Exercise | A | 0.00 | 13,927 | 0 | 13,927 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | James Steven P | Director | Payment of Exercise | F | 3.34 | 537 | 1,794 | 5,103 | 5.6 K to 5.1 K (-9.52 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | James Steven P | Director | Buy | M | 0.00 | 2,148 | 0 | 5,640 | 3.5 K to 5.6 K (+61.51 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | HENNEY CHRISTOPHER S | Director | Option Exercise | M | 0.00 | 2,148 | 0 | 0 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | HENNEY CHRISTOPHER S | Director | Option Exercise | A | 0.00 | 13,927 | 0 | 13,927 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | HENNEY CHRISTOPHER S | Director | Payment of Exercise | F | 3.34 | 537 | 1,794 | 51,611 | 52.1 K to 51.6 K (-1.03 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | HENNEY CHRISTOPHER S | Director | Buy | M | 0.00 | 2,148 | 0 | 52,148 | 50 K to 52.1 K (+4.30 %) |
Jun 13 2017 | CASC | Cascadian Therapeu ... | Fyfe Gwen A. | Director | Option Exercise | A | 0.00 | 13,927 | 0 | 13,927 | |
Jun 13 2017 | CASC | Cascadian Therapeu ... | Azelby Robert | Director | Option Exercise | A | 0.00 | 13,927 | 0 | 13,927 | |
May 16 2017 | CASC | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Buy | P | 4.00 | 2,800 | 11,192 | 44,216 | 41.4 K to 44.2 K (+6.76 %) |
Apr 04 2017 | CASC | Cascadian Therapeu ... | Azelby Robert | Director | Option Exercise | A | 0.00 | 12,437 | 0 | 12,437 | |
Apr 04 2017 | CASC | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Buy | P | 4.11 | 2,000 | 8,229 | 41,416 | 39.4 K to 41.4 K (+5.07 %) |
Mar 30 2017 | CASC | Cascadian Therapeu ... | Fyfe Gwen A. | Director | Buy | P | 4.12 | 1,666 | 6,857 | 3,332 | 1.7 K to 3.3 K (+100.00 %) |
Mar 21 2017 | CASC | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Buy | P | 3.93 | 1,000 | 3,927 | 39,416 | 38.4 K to 39.4 K (+2.60 %) |
Mar 14 2017 | CASC | Cascadian Therapeu ... | James Steven P | Director | Option Exercise | M | 0.00 | 4,656 | 0 | 0 | |
Mar 14 2017 | CASC | Cascadian Therapeu ... | James Steven P | Director | Payment of Exercise | F | 4.35 | 1,164 | 5,063 | 3,492 | 4.7 K to 3.5 K (-25.00 %) |
Mar 14 2017 | CASC | Cascadian Therapeu ... | James Steven P | Director | Buy | M | 0.00 | 4,656 | 0 | 4,656 | 0 to 4.7 K |
Feb 03 2017 | ONTY | Cascadian Therapeu ... | LOVE TED W | Director | Buy | P | 4.24 | 23,000 | 97,520 | 27,209 | 4.2 K to 27.2 K (+546.45 %) |
Feb 01 2017 | ONTY | Cascadian Therapeu ... | HENNEY CHRISTOPHER S | Director | Buy | P | 4.11 | 25,324 | 103,973 | 50,000 | 24.7 K to 50 K (+102.63 %) |
Jan 31 2017 | ONTY | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Buy | P | 3.76 | 20,500 | 77,039 | 38,416 | 17.9 K to 38.4 K (+114.42 %) |
Jan 13 2017 | ONTY | Cascadian Therapeu ... | PETERSON SCOTT ROBERT | Chief Scientific Of ... | Option Exercise | A | 0.00 | 11,300 | 0 | 11,300 | |
Jan 13 2017 | ONTY | Cascadian Therapeu ... | PETERSON SCOTT ROBERT | Chief Scientific Of ... | Option Exercise | A | 4.64 | 51,200 | 237,568 | 51,200 | |
Jan 13 2017 | ONTY | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Option Exercise | A | 0.00 | 42,000 | 0 | 42,000 | |
Jan 13 2017 | ONTY | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Option Exercise | A | 4.64 | 190,000 | 881,600 | 190,000 | |
Jan 13 2017 | ONTY | Cascadian Therapeu ... | EASTLAND JULIA MARIE | CFO & VP Corp. Dev. | Option Exercise | A | 0.00 | 11,300 | 0 | 11,300 | |
Jan 13 2017 | ONTY | Cascadian Therapeu ... | EASTLAND JULIA MARIE | CFO & VP Corp. Dev. | Option Exercise | A | 4.64 | 51,200 | 237,568 | 51,200 | |
Jan 13 2017 | ONTY | Cascadian Therapeu ... | Christianson Gary | Chief Operating Off ... | Option Exercise | A | 0.00 | 11,300 | 0 | 11,300 | |
Jan 13 2017 | ONTY | Cascadian Therapeu ... | Christianson Gary | Chief Operating Off ... | Option Exercise | A | 4.64 | 51,200 | 237,568 | 51,200 | |
Aug 18 2016 | ONTY | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Buy | P | 1.15 | 45,000 | 51,746 | 107,500 | 62.5 K to 107.5 K (+72.00 %) |
Jun 28 2016 | ONTY | Cascadian Therapeu ... | Myers Scott Dunseth | President and CEO | Buy | P | 0.80 | 62,500 | 50,000 | 62,500 | 0 to 62.5 K |
Jun 28 2016 | ONTY | Cascadian Therapeu ... | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 0.00 | 54,347 | 0 | 54,347 | |
Jun 28 2016 | ONTY | Cascadian Therapeu ... | LOVE TED W | Director | Option Exercise | A | 0.00 | 54,347 | 0 | 54,347 | |
Jun 28 2016 | ONTY | Cascadian Therapeu ... | James Steven P | Director | Option Exercise | A | 0.00 | 54,347 | 0 | 54,347 | |
Jun 28 2016 | ONTY | Cascadian Therapeu ... | Jackson Richard L. | Director | Option Exercise | A | 0.00 | 54,347 | 0 | 54,347 | |
Jun 28 2016 | ONTY | Cascadian Therapeu ... | HENNEY CHRISTOPHER S | Interim CEO and Pre ... | Option Exercise | A | 0.00 | 54,347 | 0 | 54,347 | |
Jun 28 2016 | ONTY | Cascadian Therapeu ... | Fyfe Gwen A. | Director | Option Exercise | A | 0.00 | 54,347 | 0 | 54,347 | |
Jun 27 2016 | ONTY | Cascadian Therapeu ... | LAMPERT MARK N | Director | Option Exercise | A | 0.80 | 6,197 | 4,958 | 6,197 | |
Jun 27 2016 | ONTY | Cascadian Therapeu ... | LAMPERT MARK N | Director | Option Exercise | A | 0.80 | 1,029 | 823 | 1,029 | |
Jun 27 2016 | ONTY | Cascadian Therapeu ... | LAMPERT MARK N | Director | Option Exercise | A | 0.80 | 4,519 | 3,615 | 4,519 | |
Jun 27 2016 | ONTY | Cascadian Therapeu ... | LAMPERT MARK N | Director | Option Exercise | A | 0.80 | 5,505 | 4,404 | 5,505 | |
May 19 2016 | ONTY | Oncothyreon Inc. | PETERSON SCOTT ROBERT | Chief Scientific Of ... | Option Exercise | A | 1.15 | 325,000 | 373,750 | 325,000 | |
May 19 2016 | ONTY | Oncothyreon Inc. | EASTLAND JULIA MARIE | CFO & VP Corp. Dev. | Option Exercise | A | 1.15 | 300,000 | 345,000 | 300,000 | |
May 19 2016 | ONTY | Oncothyreon Inc. | Christianson Gary | Chief Operating Off ... | Option Exercise | A | 1.15 | 250,000 | 287,500 | 250,000 | |
Apr 06 2016 | ONTY | Oncothyreon Inc. | Myers Scott Dunseth | President and CEO | Option Exercise | A | 1.18 | 2,848,855 | 3,361,649 | 2,848,855 | |
Mar 16 2016 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Interim CEO and Pre ... | Option Exercise | A | 1.06 | 150,000 | 159,000 | 150,000 | |
Sep 28 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 0.00 | 14,245 | 0 | 14,245 | |
Sep 28 2015 | ONTY | Oncothyreon Inc. | PETERSON SCOTT ROBERT | Chief Scientific Of ... | Option Exercise | A | 3.51 | 250,000 | 877,500 | 250,000 | |
Sep 28 2015 | ONTY | Oncothyreon Inc. | LOVE TED W | Director | Option Exercise | A | 0.00 | 14,245 | 0 | 14,245 | |
Sep 28 2015 | ONTY | Oncothyreon Inc. | KIRKMAN ROBERT L | President & CEO | Option Exercise | A | 3.51 | 750,000 | 2,632,500 | 750,000 | |
Sep 28 2015 | ONTY | Oncothyreon Inc. | James Steven P | Director | Option Exercise | A | 0.00 | 14,245 | 0 | 14,245 | |
Sep 28 2015 | ONTY | Oncothyreon Inc. | Jackson Richard L. | Director | Option Exercise | A | 0.00 | 14,245 | 0 | 14,245 | |
Sep 28 2015 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Director | Option Exercise | A | 0.00 | 14,245 | 0 | 14,245 | |
Sep 28 2015 | ONTY | Oncothyreon Inc. | HAUSMAN DIANA | Chief Medical Offic ... | Option Exercise | A | 3.51 | 250,000 | 877,500 | 250,000 | |
Sep 28 2015 | ONTY | Oncothyreon Inc. | EASTLAND JULIA MARIE | CFO & VP Corp. Dev. | Option Exercise | A | 3.51 | 250,000 | 877,500 | 250,000 | |
Sep 28 2015 | ONTY | Oncothyreon Inc. | Christianson Gary | Chief Operating Off ... | Option Exercise | A | 3.51 | 250,000 | 877,500 | 250,000 | |
Sep 09 2015 | ONTY | Oncothyreon Inc. | LOVE TED W | Director | Option Exercise | M | 0.00 | 17,341 | 0 | 0 | |
Sep 09 2015 | ONTY | Oncothyreon Inc. | LOVE TED W | Director | Payment of Exercise | F | 3.25 | 4,336 | 14,092 | 13,005 | 17.3 K to 13 K (-25.00 %) |
Sep 09 2015 | ONTY | Oncothyreon Inc. | LOVE TED W | Director | Buy | M | 0.00 | 17,341 | 0 | 17,341 | 0 to 17.3 K |
Jun 16 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Option Exercise | M | 0.00 | 16,042 | 0 | 0 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 0.00 | 12,886 | 0 | 12,886 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Payment of Exercise | F | 3.88 | 4,011 | 15,563 | 52,675 | 56.7 K to 52.7 K (-7.08 %) |
Jun 16 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Buy | M | 0.00 | 16,042 | 0 | 56,686 | 40.6 K to 56.7 K (+39.47 %) |
Jun 16 2015 | ONTY | Oncothyreon Inc. | LOVE TED W | Director | Option Exercise | A | 0.00 | 12,886 | 0 | 12,886 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | James Steven P | Director | Option Exercise | A | 0.00 | 12,886 | 0 | 12,886 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | Jackson Richard L. | Director | Option Exercise | M | 0.00 | 16,042 | 0 | 0 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | Jackson Richard L. | Director | Option Exercise | A | 0.00 | 12,886 | 0 | 12,886 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | Jackson Richard L. | Director | Payment of Exercise | F | 3.88 | 4,011 | 15,563 | 59,557 | 63.6 K to 59.6 K (-6.31 %) |
Jun 16 2015 | ONTY | Oncothyreon Inc. | Jackson Richard L. | Director | Buy | M | 0.00 | 16,042 | 0 | 63,568 | 47.5 K to 63.6 K (+33.75 %) |
Jun 16 2015 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Director | Option Exercise | M | 0.00 | 16,042 | 0 | 0 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Director | Option Exercise | A | 0.00 | 12,886 | 0 | 12,886 | |
Jun 16 2015 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Director | Payment of Exercise | F | 3.88 | 4,011 | 15,563 | 135,807 | 139.8 K to 135.8 K (-2.87 %) |
Jun 16 2015 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Director | Buy | M | 0.00 | 16,042 | 0 | 139,818 | 123.8 K to 139.8 K (+12.96 %) |
Jun 03 2015 | ONTY | Oncothyreon Inc. | HAUSMAN DIANA | Chief Medical Offic ... | Buy | P | 4.65 | 5,747 | 26,724 | 5,747 | 0 to 5.7 K |
Apr 01 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Buy | P | 1.59 | 10,000 | 15,856 | 40,644 | 30.6 K to 40.6 K (+32.63 %) |
Apr 01 2015 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Buy | P | 1.63 | 10,000 | 16,271 | 30,644 | 20.6 K to 30.6 K (+48.44 %) |
Mar 13 2015 | ONTY | Oncothyreon Inc. | James Steven P | Director | Option Exercise | A | 0.00 | 27,932 | 0 | 27,932 | |
Feb 09 2015 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 1.50 | 1,400 | 2,100 | 1,400 | |
Feb 09 2015 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 1.50 | 2,600 | 3,900 | 2,600 | |
Feb 09 2015 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 1,400,000 | 0 | 1,898,293 | 3.3 M to 1.9 M (-42.45 %) |
Feb 09 2015 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 2,600,000 | 0 | 3,762,683 | 6.4 M to 3.8 M (-40.86 %) |
Dec 17 2014 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.73 | 55,197 | 95,662 | 3,298,293 | 3.2 M to 3.3 M (+1.70 %) |
Dec 17 2014 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.73 | 98,298 | 170,360 | 6,362,683 | 6.3 M to 6.4 M (+1.57 %) |
Dec 17 2014 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.88 | 79,434 | 149,249 | 3,243,096 | 3.2 M to 3.2 M (+2.51 %) |
Dec 17 2014 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 1.88 | 145,515 | 273,408 | 6,264,385 | 6.1 M to 6.3 M (+2.38 %) |
Dec 16 2014 | ONTY | Oncothyreon Inc. | Venkatesan Jay | EVP and General Man ... | Option Exercise | A | 1.76 | 100,000 | 176,000 | 100,000 | |
Dec 16 2014 | ONTY | Oncothyreon Inc. | PETERSON SCOTT ROBERT | Chief Scientific Of ... | Option Exercise | A | 1.76 | 150,000 | 264,000 | 150,000 | |
Dec 16 2014 | ONTY | Oncothyreon Inc. | KIRKMAN ROBERT L | President & CEO | Option Exercise | A | 1.76 | 300,000 | 528,000 | 300,000 | |
Dec 16 2014 | ONTY | Oncothyreon Inc. | HAUSMAN DIANA | Chief Medical Offic ... | Option Exercise | A | 1.76 | 150,000 | 264,000 | 150,000 | |
Dec 16 2014 | ONTY | Oncothyreon Inc. | EASTLAND JULIA MARIE | CFO & VP Corp. Dev. | Option Exercise | A | 1.76 | 100,000 | 176,000 | 100,000 | |
Dec 16 2014 | ONTY | Oncothyreon Inc. | Christianson Gary | Chief Operating Off ... | Option Exercise | A | 1.76 | 100,000 | 176,000 | 100,000 | |
Oct 08 2014 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Sell | S | 1.72 | 3,403 | 5,854 | 20,644 | 24 K to 20.6 K (-14.15 %) |
Oct 08 2014 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Sell | S | 1.96 | 12,780 | 25,054 | 24,047 | 36.8 K to 24 K (-34.70 %) |
Sep 25 2014 | ONTY | Oncothyreon Inc. | Venkatesan Jay | EVP and General Man ... | Grant | A | 2.00 | 250,000 | 500,000 | 250,000 | 0 to 250 K |
Sep 05 2014 | ONTY | Oncothyreon Inc. | Venkatesan Jay | EVP and General Man ... | Option Exercise | A | 2.24 | 100,000 | 224,000 | 100,000 | |
Aug 12 2014 | ONTY | Oncothyreon Inc. | Venkatesan Jay | EVP and General Man ... | Grant | A | 0.00 | 263,493 | 0 | 263,493 | 0 to 263.5 K |
Aug 12 2014 | ONTY | Oncothyreon Inc. | Venkatesan Jay | EVP and General Man ... | Grant | A | 0.00 | 3,776,723 | 0 | 3,826,723 | 50 K to 3.8 M (+7,553.45 %) |
Jul 16 2014 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | Option Exercise | J | 5.00 | 242,814 | 1,214,070 | 1,223,484 | ||
Jul 16 2014 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | Option Exercise | J | 5.00 | 407,136 | 2,035,680 | 2,288,698 | ||
Jul 16 2014 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | Sell | J | 3.24 | 258,230 | 836,665 | 2,412,290 | 2.7 M to 2.4 M (-9.67 %) | |
Jul 16 2014 | ONTY | Oncothyreon Inc. | BVF PARTNERS L P/IL | Sell | J | 3.24 | 296,008 | 959,066 | 4,512,523 | 4.8 M to 4.5 M (-6.16 %) | |
Jun 10 2014 | ONTY | Oncothyreon Inc. | STOUGHTON W. VICKERY | Director | Option Exercise | A | 0.00 | 16,339 | 0 | 16,339 | |
Jun 10 2014 | ONTY | Oncothyreon Inc. | STOUGHTON W. VICKERY | Director | Payment of Exercise | F | 3.06 | 2,044 | 6,255 | 46,692 | 48.7 K to 46.7 K (-4.19 %) |
Jun 10 2014 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Option Exercise | A | 0.00 | 16,339 | 0 | 16,339 | |
Jun 10 2014 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Payment of Exercise | F | 3.06 | 2,044 | 6,255 | 36,827 | 38.9 K to 36.8 K (-5.26 %) |
Jun 10 2014 | ONTY | Oncothyreon Inc. | LOVE TED W | Director | Option Exercise | A | 0.00 | 16,339 | 0 | 16,339 | |
Jun 10 2014 | ONTY | Oncothyreon Inc. | Jackson Richard L. | Director | Option Exercise | A | 0.00 | 16,339 | 0 | 16,339 | |
Jun 10 2014 | ONTY | Oncothyreon Inc. | Jackson Richard L. | Director | Payment of Exercise | F | 3.06 | 2,044 | 6,255 | 47,526 | 49.6 K to 47.5 K (-4.12 %) |
Jun 10 2014 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Director | Option Exercise | A | 0.00 | 16,339 | 0 | 16,339 | |
Jun 10 2014 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Director | Payment of Exercise | F | 3.06 | 2,044 | 6,255 | 123,776 | 125.8 K to 123.8 K (-1.62 %) |
Mar 12 2014 | ONTY | Oncothyreon Inc. | STOUGHTON W. VICKERY | Director | Option Exercise | M | 0.00 | 19,352 | 0 | 0 | |
Mar 12 2014 | ONTY | Oncothyreon Inc. | STOUGHTON W. VICKERY | Director | Payment of Exercise | F | 3.65 | 4,838 | 17,659 | 48,736 | 53.6 K to 48.7 K (-9.03 %) |
Mar 12 2014 | ONTY | Oncothyreon Inc. | STOUGHTON W. VICKERY | Director | Buy | M | 0.00 | 19,352 | 0 | 53,574 | 34.2 K to 53.6 K (+56.55 %) |
Mar 12 2014 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Option Exercise | M | 0.00 | 19,352 | 0 | 0 | |
Mar 12 2014 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Payment of Exercise | F | 3.65 | 4,838 | 17,659 | 38,871 | 43.7 K to 38.9 K (-11.07 %) |
Mar 12 2014 | ONTY | Oncothyreon Inc. | SPIEGELMAN DANIEL K | Director | Buy | M | 0.00 | 19,352 | 0 | 43,709 | 24.4 K to 43.7 K (+79.45 %) |
Mar 12 2014 | ONTY | Oncothyreon Inc. | Jackson Richard L. | Director | Option Exercise | M | 0.00 | 19,352 | 0 | 0 | |
Mar 12 2014 | ONTY | Oncothyreon Inc. | Jackson Richard L. | Director | Payment of Exercise | F | 3.65 | 4,838 | 17,659 | 49,570 | 54.4 K to 49.6 K (-8.89 %) |
Mar 12 2014 | ONTY | Oncothyreon Inc. | Jackson Richard L. | Director | Buy | M | 0.00 | 19,352 | 0 | 54,408 | 35.1 K to 54.4 K (+55.20 %) |
Mar 12 2014 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Director | Option Exercise | M | 0.00 | 19,352 | 0 | 0 | |
Mar 12 2014 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Director | Payment of Exercise | F | 3.65 | 4,838 | 17,659 | 125,820 | 130.7 K to 125.8 K (-3.70 %) |
Mar 12 2014 | ONTY | Oncothyreon Inc. | HENNEY CHRISTOPHER S | Director | Buy | M | 0.00 | 19,352 | 0 | 130,658 | 111.3 K to 130.7 K (+17.39 %) |
Dec 16 2013 | ONTY | Oncothyreon Inc. | PETERSON SCOTT ROBERT | Chief Scientific Of ... | Option Exercise | A | 1.74 | 150,000 | 261,000 | 150,000 | |
Dec 16 2013 | ONTY | Oncothyreon Inc. | KIRKMAN ROBERT L | President & CEO | Option Exercise | A | 1.74 | 600,000 | 1,044,000 | 600,000 |